ChristineLeeHannMDPhD

Oncology • Baltimore, MD

Assistant Professor of Oncology, Johns Hopkins University School of Medicine; Assistant Professor of Oncology

Join to view full profile

Dr. Hann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hann's full profile

Already have an account?

Office
300 Mason Lord Drive
Kimmel Cancer Center
Baltimore, MD 21224
Phone+1 410-550-1711

Fax+1 410-550-1116

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
University of ChicagoResidency, Internal Medicine, 2000 - 2002
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

MD State Medical License 2003 - 2026
PA State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
IL State Medical License 2000 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Start of enrollment: 2018 Mar 20
Terminated
Phase 1, Phase 2
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Start of enrollment: 2018 Mar 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations.
Tia Cheunkarndee, Matthew Z Guo, Stefanie Houseknecht, Josephine L Feliciano, Christine L Hann
JTO Clinical and Research Reports. 2024-06-01
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski
Cancer Research Communications. 2024-03-14
Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer.
Paola Ghanem, Joseph C Murray, Melinda Hsu, Matthew Z Guo, David S Ettinger
Clinical Lung Cancer. 2024-03-01

Lectures

New Options in Small Cell Lung Cancer: To Immunotherapy or Not
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

OncLive® Presents the Latest State of the Science Summit™ on Advances in Lung Cancer ManagementOctober 29th, 2018

Professional Memberships

American Association for Cancer Research - AACR
Member

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/christine-hann